AU2012296905B2 - Combination therapy with an anti - CD19 antibody and a purine analog - Google Patents

Combination therapy with an anti - CD19 antibody and a purine analog Download PDF

Info

Publication number
AU2012296905B2
AU2012296905B2 AU2012296905A AU2012296905A AU2012296905B2 AU 2012296905 B2 AU2012296905 B2 AU 2012296905B2 AU 2012296905 A AU2012296905 A AU 2012296905A AU 2012296905 A AU2012296905 A AU 2012296905A AU 2012296905 B2 AU2012296905 B2 AU 2012296905B2
Authority
AU
Australia
Prior art keywords
lymphoma
seq
sequence
region
fludarabine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012296905A
Other languages
English (en)
Other versions
AU2012296905A1 (en
Inventor
Jutta AMERSDORFFER
Susanne KROHN
Lisa Rojkjaer
Stefan Steidl
Mark Winderlich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of AU2012296905A1 publication Critical patent/AU2012296905A1/en
Application granted granted Critical
Publication of AU2012296905B2 publication Critical patent/AU2012296905B2/en
Assigned to INCYTE CORPORATION reassignment INCYTE CORPORATION Request for Assignment Assignors: MORPHOSYS AG
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2012296905A 2011-08-16 2012-08-14 Combination therapy with an anti - CD19 antibody and a purine analog Active AU2012296905B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161523862P 2011-08-16 2011-08-16
EP11177660 2011-08-16
EP11177660.5 2011-08-16
US61/523,862 2011-08-16
PCT/EP2012/065904 WO2013024095A1 (en) 2011-08-16 2012-08-14 Combination therapy with an anti - cd19 antibody and a purine analog

Publications (2)

Publication Number Publication Date
AU2012296905A1 AU2012296905A1 (en) 2013-12-05
AU2012296905B2 true AU2012296905B2 (en) 2017-01-05

Family

ID=47714800

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012296905A Active AU2012296905B2 (en) 2011-08-16 2012-08-14 Combination therapy with an anti - CD19 antibody and a purine analog

Country Status (25)

Country Link
US (3) US20140227277A1 (enExample)
EP (2) EP2744826B1 (enExample)
JP (1) JP6114273B2 (enExample)
KR (3) KR20140071368A (enExample)
CN (1) CN103703027B (enExample)
AU (1) AU2012296905B2 (enExample)
BR (1) BR112013033916B1 (enExample)
CA (1) CA2841738C (enExample)
CY (1) CY1125148T1 (enExample)
DK (1) DK2744826T3 (enExample)
ES (1) ES2909720T3 (enExample)
HR (1) HRP20220224T1 (enExample)
HU (1) HUE058855T2 (enExample)
IL (1) IL230295B (enExample)
LT (1) LT2744826T (enExample)
MX (1) MX353589B (enExample)
PL (1) PL2744826T3 (enExample)
PT (1) PT2744826T (enExample)
RS (1) RS63121B1 (enExample)
RU (1) RU2664462C9 (enExample)
SG (1) SG10201606788VA (enExample)
SI (1) SI2744826T1 (enExample)
SM (1) SMT202200160T1 (enExample)
WO (1) WO2013024095A1 (enExample)
ZA (1) ZA201401835B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2514591A (en) * 2013-05-30 2014-12-03 Mologen Ag Predictive biomarker for cancer therapy
ES2523901B1 (es) * 2013-05-31 2015-12-02 Universidad Autónoma de Madrid Uso de la deguelina como terapia suplementaria de la leucemia linfoide crónica
WO2015195498A1 (en) * 2014-06-16 2015-12-23 Xencor, Inc. Treatment for chronic lymphocytic leukemia (cll)
IL249533A0 (en) * 2014-06-16 2017-02-28 Xencor Inc Treatment of chronic lymphocytic leukemia
KR102809079B1 (ko) * 2015-05-26 2025-05-21 인사이트 코포레이션 항-cd19 항체 및 브루톤 타이로신 키나제 억제제의 조합 및 이의 용도
LT3337506T (lt) * 2015-08-21 2021-10-11 Morphosys Ag Deriniai ir jų panaudojimas
BR112018074603A2 (pt) * 2016-05-30 2019-03-19 Morphosys Ag método para identificar um sujeito tendo leucemia linfocítica crônica, método para selecionar um paciente para tratamento e utilização de um anticorpo
IL301786B2 (en) * 2016-10-28 2025-09-01 Morphosys Ag Combination of anti-CD19 antibody with BCL-2 inhibitor and their uses
HRP20231229T1 (hr) * 2017-05-31 2024-02-02 Morphosys Ag Paradigma liječenja za protutijelo anti-cd19 i venetoklaks kombinacijsko liječenje
EP3652206A1 (en) 2017-07-10 2020-05-20 International-Drug-Development-Biotech Treatment of b cell malignancies using afucosylated pro-apoptotic anti-cd19 antibodies in combination with anti cd20 antibodies or chemotherapeutics
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
WO2020150513A1 (en) * 2019-01-17 2020-07-23 Fred Hutchinson Cancer Research Center Methods to enhance the selectivity and effectiveness of cancer treatments
EP4453033A1 (en) * 2021-12-22 2024-10-30 Incyte Corporation Treatment paradigm for an anti-cd19 antibody therapy
WO2025012080A1 (en) 2023-07-13 2025-01-16 Christian-Albrechts-Universität Zu Kiel Humanized anti-cd7 antibody

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11852A (en) 1854-10-31 Abraham bassford
US106A (en) 1915-08-24 Specipication
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
EP1974747B1 (en) * 1998-08-11 2012-06-27 Biogen Idec Inc. Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody
DE60042785D1 (de) 1999-06-09 2009-10-01 Immunomedics Inc Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern
KR20040023565A (ko) 2000-09-18 2004-03-18 아이덱 파마슈티칼즈 코포레이션 Ｂ 세포 고갈/면역조절 항체 조합을 이용한 자가면역질환의 치료를 위한 조합 요법
DE60226641D1 (de) 2001-12-03 2008-06-26 Amgen Fremont Inc Antikörperkategorisierung auf der grundlage von bindungseigenschaften
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
US7109304B2 (en) 2003-07-31 2006-09-19 Immunomedics, Inc. Humanized anti-CD19 antibodies
US8444973B2 (en) 2005-02-15 2013-05-21 Duke University Anti-CD19 antibodies and uses in B cell disorders
EP1899379B1 (en) 2005-06-20 2018-04-11 E. R. Squibb & Sons, L.L.C. Cd19 antibodies and their uses
US20070136826A1 (en) * 2005-12-02 2007-06-14 Biogen Idec Inc. Anti-mouse CD20 antibodies and uses thereof
DK2270050T3 (da) 2005-12-30 2013-08-12 Merck Patent Gmbh Anti-CD19-antistoffer med nedsat immunogenicitet
DK2059536T3 (da) * 2006-08-14 2014-04-14 Xencor Inc Optimerede antistoffer, der er rettet mod cd19
WO2008031056A2 (en) 2006-09-08 2008-03-13 Medimmune, Llc Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
WO2008150494A1 (en) 2007-05-30 2008-12-11 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
WO2009052431A2 (en) 2007-10-19 2009-04-23 Seattle Genetics, Inc. Cd19 binding agents and uses thereof
CA2753158A1 (en) 2009-02-23 2010-08-26 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
EP2445530B1 (en) 2009-06-24 2016-09-07 The Feinstein Institute for Medical Research Method for treating chronic lymphocytic leukemia
TWI409079B (zh) * 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
RU2012109451A (ru) * 2009-08-14 2013-09-27 Роше Гликарт Аг Комбинированная терапия на основе афукозилированного антитела к cd20 в сочетании с флударабином и/или митоксантроном
CA2779424A1 (en) * 2009-11-06 2011-05-12 Infinity Pharmaceuticals, Inc. Oral formulations of a hedgehog pathway inhibitor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KOCHENDERFER J. et al, Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19, Blood, 2010, Vol. 116(20), pp 4099-4102 *

Also Published As

Publication number Publication date
EP2744826B1 (en) 2022-02-09
LT2744826T (lt) 2022-04-25
MX2013014935A (es) 2014-07-09
SG10201606788VA (en) 2016-09-29
KR102117202B1 (ko) 2020-06-01
KR20140071368A (ko) 2014-06-11
KR20200060779A (ko) 2020-06-01
ES2909720T3 (es) 2022-05-10
RU2664462C2 (ru) 2018-08-17
PT2744826T (pt) 2022-05-19
EP4083071A2 (en) 2022-11-02
ZA201401835B (en) 2015-06-24
RU2014103490A (ru) 2015-09-27
CN103703027A (zh) 2014-04-02
US20240424012A1 (en) 2024-12-26
CA2841738C (en) 2022-12-06
IL230295B (en) 2018-03-29
US20200352975A1 (en) 2020-11-12
HRP20220224T1 (hr) 2022-04-29
CN103703027B (zh) 2018-01-12
SMT202200160T1 (it) 2022-05-12
EP4083071A3 (en) 2023-02-22
JP6114273B2 (ja) 2017-04-12
JP2014525925A (ja) 2014-10-02
CY1125148T1 (el) 2024-12-13
SI2744826T1 (sl) 2022-05-31
CA2841738A1 (en) 2013-02-21
PL2744826T3 (pl) 2022-05-30
NZ617771A (en) 2016-01-29
BR112013033916B1 (pt) 2022-11-16
DK2744826T3 (da) 2022-03-28
RS63121B1 (sr) 2022-05-31
RU2664462C9 (ru) 2018-09-28
WO2013024095A1 (en) 2013-02-21
EP2744826A1 (en) 2014-06-25
MX353589B (es) 2018-01-19
KR20190094478A (ko) 2019-08-13
US20140227277A1 (en) 2014-08-14
BR112013033916A2 (pt) 2017-11-28
HUE058855T2 (hu) 2022-09-28

Similar Documents

Publication Publication Date Title
US20240424012A1 (en) Combinations and uses thereof
US20240009196A1 (en) Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
US12194095B2 (en) Combinations and uses thereof
AU2012296905A1 (en) Combination therapy with an anti - CD19 antibody and a purine analog
AU2012296907B2 (en) Combination therapy with an anti - CD19 antibody and a nitrogen mustard
JP2014525925A5 (enExample)
AU2012296907A1 (en) Combination therapy with an anti - CD19 antibody and a nitrogen mustard
HK40081594A (en) Combination therapy with an anti-cd19 antibody and a nitrogen mustard
HK40069168A (en) Combinations and uses thereof
NZ617771B2 (en) Combination therapy with an anti - cd19 antibody and a purine analog
HK1195322A (en) Combination therapy with an anti-cd19 antibody and a purine analog
HK1195322B (en) Combination therapy with an anti-cd19 antibody and a purine analog

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: INCYTE CORPORATION

Free format text: FORMER OWNER(S): MORPHOSYS AG